<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03437369</url>
  </required_header>
  <id_info>
    <org_study_id>HURamonyCajal</org_study_id>
    <nct_id>NCT03437369</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety on Heart Rate Control With Ivabradine on Cardiogenic Shock</brief_title>
  <acronym>ES-FISH</acronym>
  <official_title>Efficacy and Safety on Heart Rate Control With Ivabradine on Cardiogenic Shock (ES-FISH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitario Ramon y Cajal</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitario Ramon y Cajal</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized 1:1 blinded study that evaluate in acute left heart failure-cardiogenic
      shock patients if ivabradine treatment can reduce pulmonary wedge pressure, without inducing
      a significant or relevant reduction in cardiac output or increasing the risk of arterial
      hypotension and with the benefit of allowing a faster titration of heart failure drugs.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2018</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes from baseline in pulmonary wedge pressure and cardiac output after 24h-treatment with ivabradine or standard of care treatment.</measure>
    <time_frame>24 hours</time_frame>
    <description>Reduction of pulmonary wedge pressure from baseline in both treatment arms (ivabradine arm versus standard of care treatment measured by Swan Ganz balloon flotation catheter)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Severe bradycardia</measure>
    <time_frame>24 hours</time_frame>
    <description>-Development of excessive bradycardia defined as heart rate (HR) &lt;50 beats per minute</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arrhythmias</measure>
    <time_frame>24 hours</time_frame>
    <description>New-onset of ventricular arrhythmias or atrial fibrillation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypotension</measure>
    <time_frame>24 hours</time_frame>
    <description>Hypotension, defined as systolic blood pressure &lt;90 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to withdrawal of vasoactive drugs</measure>
    <time_frame>30 days</time_frame>
    <description>-Time to catecholamine withdrawal in both treatment arms (days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time needing invasive mechanical ventilation</measure>
    <time_frame>30 days</time_frame>
    <description>Mechanical (invasive) ventilation time after initiation of ivabradine/control treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>B-type natriuretic peptide (BNP)</measure>
    <time_frame>30 days</time_frame>
    <description>Measured B-type natriuretic peptide (BNP) values at 30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular ejection fraction</measure>
    <time_frame>30 days</time_frame>
    <description>Change in left ventricle ejection fraction from baseline in both treatment arms (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular mortality</measure>
    <time_frame>30 days</time_frame>
    <description>Mortality due to cardiovascular causes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total mortality</measure>
    <time_frame>30 days</time_frame>
    <description>Mortality from any cause</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">22</enrollment>
  <condition>Cardiogenic Shock</condition>
  <arm_group>
    <arm_group_label>Ivabradine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Ivabradine Oral tablets 2.5 mg Dose: 10-15 mg/day Duration: 30 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The study drug will be compared with standard of Care treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivabradine Oral Tablet</intervention_name>
    <description>The target dose is 10 to 15 mg / day, administered orally in two doses</description>
    <arm_group_label>Ivabradine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of Care treatment</intervention_name>
    <description>The study drug will be compared with the standard of Care treatment</description>
    <arm_group_label>Standard of Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged ≥ 18 years, with acute heart failure due to left ventricular systolic
             dysfunction (LVEF ≤ 40%) in sinus rhythm, baseline HR ≥ 90 bpm, with signs of low
             peripheral perfusion with indication for intravenous inotropic treatment
             (catecholamines: dobutamine , adrenaline, dopamine or noradrenaline) and admitted to
             the Cardiological Intensive Care Unit.

          -  Pharmacological treatment and stable hemodynamic situation in the 4 hours before
             inclusion.

          -  Pulmonary wedge pressure ≥ 18 mm Hg and systolic blood pressure &gt; 90 mm Hg.

          -  Patient's signature on the consent form.

        Exclusion Criteria:

          -  Previous treatment with ivabradine (&lt; 48 hours).

          -  Known hypersensitivity to ivabradine.

          -  Cardiac rhythm different from sinus rhythm.

          -  Unstable cardiac rhythm due to paroxysmal atrial fibrillation or atrial flutter, very
             frequent ventricular or supraventricular premature beats, ventricular tachycardia, 2nd
             or 3rd degree atrioventricular (AV) block.

          -  Severe chronic renal failure (estimated glomerular filtration rate ≤15 ml / min) or on
             chronic treatment with dialysis.

          -  QT interval higher than 450 ms.

          -  Sepsis as a probable mechanism of tachycardia and hypotension.

          -  Need for urgent cardiac surgery, planned within 72 hours of possible inclusion.

          -  Severe aortic stenosis or severe valvular disease that requires surgical correction.

          -  Patient must not have received an IV bolus of furosemide immediately before the
             baseline hemodynamic assessment.

          -  Severe hepatic insufficiency.

          -  Patient must not be participating in another clinical trial.

          -  Concomitant use of potent CYP3A4 inhibitors.

          -  Acute anemia or hypovolemia uncorrected.

          -  Pregnancy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marcelo Sanmartín Fernández, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Ramon y Cajal</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marcelo Sanmartín Fernández, PhD</last_name>
    <phone>+34 91 336 80 00</phone>
    <email>msanfer@me.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marcelo Sanmartin, MD</last_name>
      <phone>+34 91 336 80 00</phone>
      <email>msanfer@me.com</email>
    </contact>
    <investigator>
      <last_name>Marina Pascual Izco, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luis Miguel Rincón Díaz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gonzalo Luis Alonso Salinas, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Manuel Jimenez Mena, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Asunción Camino González, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jose Luis Zamorano, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marcelo Sanmartín Fernandez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Tardif JC, Ford I, Tendera M, Bourassa MG, Fox K; INITIATIVE Investigators. Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J. 2005 Dec;26(23):2529-36. Epub 2005 Oct 7.</citation>
    <PMID>16214830</PMID>
  </reference>
  <reference>
    <citation>Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L; SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010 Sep 11;376(9744):875-85. doi: 10.1016/S0140-6736(10)61198-1. Erratum in: Lancet. 2010 Dec 11;376(9757):1988. Lajnscak, M [corrected to Lainscak, M]; Rabanedo, I Roldan [corrected to Rabadán, I Roldan]; Leva, M [corrected to Ieva, M].</citation>
    <PMID>20801500</PMID>
  </reference>
  <reference>
    <citation>Fasullo S, Cannizzaro S, Maringhini G, Ganci F, Giambanco F, Vitale G, Pinto V, Migliore G, Torres D, Sarullo FM, Paterna S, Di Pasquale P. Comparison of ivabradine versus metoprolol in early phases of reperfused anterior myocardial infarction with impaired left ventricular function: preliminary findings. J Card Fail. 2009 Dec;15(10):856-63. doi: 10.1016/j.cardfail.2009.05.013. Epub 2009 Jul 3.</citation>
    <PMID>19944362</PMID>
  </reference>
  <reference>
    <citation>Lechat P, Hulot JS, Escolano S, Mallet A, Leizorovicz A, Werhlen-Grandjean M, Pochmalicki G, Dargie H. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial. Circulation. 2001 Mar 13;103(10):1428-33.</citation>
    <PMID>11245648</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 15, 2018</study_first_submitted>
  <study_first_submitted_qc>February 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 19, 2018</study_first_posted>
  <last_update_submitted>February 12, 2018</last_update_submitted>
  <last_update_submitted_qc>February 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitario Ramon y Cajal</investigator_affiliation>
    <investigator_full_name>Marcelo Sanmartín Fernández</investigator_full_name>
    <investigator_title>Director Acute Coronary Syndrome Process</investigator_title>
  </responsible_party>
  <keyword>Ivabradine, heart rate, acute heart failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock</mesh_term>
    <mesh_term>Shock, Cardiogenic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

